One‐year outcome from an all‐comers population of patients with ST‐segment elevation myocardial infarction treated with biolimus‐eluting stent with biodegradable polymer. Issue 3 (28th August 2014)

• Record Type: Journal Article
• Authors: Tomai, Fabrizio; De Luca, Leonardo; Altamura, Luca; Versaci, Francesco; Pennacchi, Mauro; Proietti, Igino; Ghini, Anna S.; Corvo, Pierfrancesco; De Persio, Giovanni; Petrolini, Alessandro; Tommasino, Antonella; Sardella, Gennaro
• Is Part Of: Catheterization and cardiovascular interventions. Volume 85:Issue 3(2015:Feb. 15)
• Page Start: 352
• Page End: 358
• Publication Date: 2014-08-28
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.25627
• Languages: English
• ISSNs: 1522-1946

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ccd25627-sec-0001" sec-type="section"> <title>Objectives</title> <p>To evaluate the performance of biolimus‐eluting stent (BES) in patients with ST‐elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) in a real world clinical scenario.</p> </sec> <sec id="ccd25627-sec-0002" sec-type="section"> <title>Background</title> <p>Randomized studies suggest that the BES with biodegradable polymer is more effective and safe than early generation coronary stents in patients with STEMI.</p> </sec> <sec id="ccd25627-sec-0003" sec-type="section"> <title>Methods</title> <p>We included all consecutive STEMI patients undergoing PCI in this prospective, multicenter registry. The primary endpoint of the study was the rate of major adverse cardiac events (MACE), a composite of cardiac death, recurrent myocardial infarction and ischemia‐driven target vessel revascularization at 1‐year follow‐up.</p> </sec> <sec id="ccd25627-sec-0004" sec-type="section"> <title>Results</title> <p>Between June and December 2012 we enrolled 311 STEMI patients. The primary endpoint occurred in 3.2% (95% confidence interval: 1.6–5.8) of patients: cardiac death, re‐infarction, and ischemia‐driven TVR occurred in 2.3%, 1.3%, and 0.6% of patients, respectively. One‐year MACE‐free survival was 96.8% ± 1.0%.</p> </sec> <sec id="ccd25627-sec-0005" sec-type="section"> <title>Conclusions</title> <p>In a real‐world cohort of STEMI patients undergoing PCI, the use of BES is associated with good 1‐year clinical outcome. These results confirm and expand previous findings showing the efficacy and safety of BES in the setting of randomized trials. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>